By MarketNewsVideo This morning, UBS increased its price target on shares of Vertex Pharmaceuticals (VRTX) to $84 to reflect the increased earnings power of Kalydeco. In the report, UBS increased its EPS estimates as well. Shares of VRTX were trading up about 4.7%. …read more
Source: FULL ARTICLE at Forbes Markets